Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Dose, Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Way Crossover Study to Evaluate the Effect of Enpatoran on the QTc (Corrected QT) Interval in Healthy Adult Participants

Next Previous
Trial Profile

A Single-Dose, Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Way Crossover Study to Evaluate the Effect of Enpatoran on the QTc (Corrected QT) Interval in Healthy Adult Participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enpatoran (Primary) ; Moxifloxacin
  • Indications COVID-19 pneumonia; Cutaneous lupus erythematosus; Dermatomyositis; Polymyositis; Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Sponsors Merck KGaA

Most Recent Events

  • 19 Dec 2024 Status changed from active, no longer recruiting to completed.
  • 03 Dec 2024 Planned End Date changed from 1 Mar 2025 to 4 Dec 2024.
  • 03 Dec 2024 Planned primary completion date changed from 1 Mar 2025 to 4 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top